Furthermore, the combination treatment moderately enhanced the cytotoxicity and augmented apoptosis in myeloma cells via suppression of the AKT/mTOR pathway and the downregulation of Bcl-2 and Mcl-1 proteins. The gene discussed is AKT1; the disease is plasma cell myeloma.